Shares of Beigene, Ltd. (NASDAQ:ONC - Get Free Report) traded down 0.1% during trading on Tuesday following insider selling activity. The stock traded as low as $260.46 and last traded at $263.42. 416,160 shares traded hands during trading, a decline of 8% from the average session volume of 450,640 shares. The stock had previously closed at $263.78.
Specifically, CEO John Oyler sold 5,127 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $252.77, for a total value of $1,295,951.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO Xiaobin Wu sold 1,934 shares of the firm's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $253.15, for a total value of $489,592.10. The disclosure for this sale can be found here. In other Beigene news, insider Lai Wang sold 1,402 shares of Beigene stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $252.39, for a total transaction of $353,850.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Wall Street Analyst Weigh In
A number of research firms recently commented on ONC. Royal Bank of Canada decreased their price objective on Beigene from $312.00 to $311.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. JPMorgan Chase & Co. boosted their price objective on shares of Beigene from $311.00 to $317.00 and gave the company an "overweight" rating in a research report on Monday, April 21st. JMP Securities set a $348.00 target price on shares of Beigene in a research note on Friday, February 28th. Bank of America upgraded Beigene from a "neutral" rating to a "buy" rating and boosted their price target for the company from $207.00 to $320.00 in a report on Monday, March 3rd. Finally, Sanford C. Bernstein set a $259.00 price objective on Beigene in a research report on Thursday, March 13th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $319.00.
View Our Latest Report on Beigene
Beigene Stock Down 0.4%
The stock has a market cap of $31.06 billion, a P/E ratio of -31.85, a price-to-earnings-growth ratio of 7.73 and a beta of 0.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The business has a 50 day moving average price of $238.58.
Beigene (NASDAQ:ONC - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business had revenue of $1.12 billion for the quarter, compared to analysts' expectations of $1.12 billion. On average, research analysts forecast that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.
About Beigene
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Featured Articles
Before you consider Beigene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beigene wasn't on the list.
While Beigene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
